Increasing evidence suggests that apoptosis may be the mechanism underlying cell death in selective loss of nigral dopaminergic neurons in Parkinson's disease (PD). Previous studies strongly suggested that c-Jun N-terminal kinase (JNK) signaling pathway has a critical role in the animal model with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD. In this study, we report the inhibitory effect of a peptide designated as Tat-JBD on JNKs activation. The sequence of Tat is corresponding to the cell-membrane transduction domain of human immunodeficiency virus-type 1 (HIV-1) and the sequence of an 11-amino acid peptide is corresponding to the residues of JNK-binding domain (JBD) on JNK-interacting protein-1 (JIP-1). Tat-JBD is confirmed to perturb the assembly of JIP-1-JNKs complex, inhibit the activation of JNKs induced by MPTP and consequently diminish the phosphorylation of c-Jun. It also inhibits the phosphorylation of Bcl-2 and the releasing of Bax from Bcl-2/Bax dimmers, sequentially attenuates the translocation of Bax to mitochondria, the release of cytochrome c, the activation of caspase3 and the hydrolyzation of poly-ADP-ribosepolymerase. The death of dopaminergic neurons and the loss of dopaminergic axon in the striatum were significantly suppressed by infusion of the peptide Tat-JBD in MPTP-treated mice. Our findings imply that Tat-JBD offers neuroprotection against MPTP injury via inhibiting the JNK-signaling pathway, and may provide a promising therapeutic approach for PD.
Parkinson's disease (PD) is a common neurodegenerative disorder in which apoptosis maybe the main cause for selective loss of dopamine-containing neurons in the midbrain. 1 Undoubtedly, effective treatments for PD depend largely on our understanding of the molecular mechanisms of the disease, which is still incomplete. Yet, significant hints into the pathogenesis of PD have been yielded by the use of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that replicates most of the neuropathological hallmarks of PD in humans. 2, 3 Although the MPTP mouse model departs from human PD in a few ways, it still offers a unique means to investigate molecular events underlying the demise of midbrain dopaminergic neurons in vivo. 2, 3 Mitogen-activated protein kinases (MAPK) have a critical role in promoting survival or inducing cell death. c-Jun N-terminal kinase (JNK), a member of MAPK family, is activated by a variety of stimuli including neurotoxic insults, environmental stress and apoptotic agents. [4] [5] [6] Activated JNK in turn phosphorylates its substrates including c-Jun, ATF-2, ELK1 and p53, leading to excitotoxicity and neuronal death. 4, 7 JNKs consist of JNK1, JNK2 and JNK3, in which JNK3 is largely restricted to the brain within neurons, whereas JNK1 and JNK2 are ubiquitously expressed. 8, 9 Examination of various JNK-deficient mice shows that both JNK2 and JNK3 are required for MPTP-induced c-Jun activation and dopaminergic cell demise.
10 JNK3 knock-out provides long-lasting protection against axotomy and it is at least transiently protective against 6-hydroxydopamine (6-OHDA). 11 This suggested that JNKs especially JNK3 may have an important role in mediating neuronal apoptosis and blockade of JNKs by specific inhibitors may prevent or effectively slow down the progression of PD. 8, 9 Previous studies have suggested that JNK-interacting protein-1 (JIP-1), one member of JNK scaffolds family, is a key factor for JNK activation. It functions as a scaffold protein and carries JNK, MKK7 and MLK3 to form MAPK cascade. The cascade formation is critical for JNK activation. 12, 13 The JNK-binding domain of JIP-1 (JBD) is located at residues 127-282, the N terminus of the protein. 14 Eilers's 15 results showed overexpression of JBD can inhibit JNK activation and reduce the apoptosis induced by the withdrawal of nerve growth factor in PC12 cells. Apoptosis was also reduced or prevented by overexpression of the JBD in the insulin-secreting cells or sympathetic neurons. [16] [17] [18] The overexpressed JBD appears to effectively inhibit the JNK pathway by disrupting the scaffolded JNK upstream components. 19 Barr 20 further reported a 11-amino acid JIP-1-derived (residues 153-163 of JIP-1) peptide can also effectively inhibit interleukin-1-induced c-jun expression and protect against interleukin-1-induced pancreatic cell apoptosis. On the basis of the above results, we synthesized the 11-mer peptide (Arg-Pro-Lys-Arg-Pro-Thr-Thr-Leu-AsnLeu-Phe) mentioned in Barr et al's 20 paper and fused it with Tat peptide (Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-ArgArg) originated from the cell-membrane transduction domain of HIV-1 to obtain a 22-amino acid fusion peptide, Tat-JBD. The peptide was evaluated in vitro to ascertain its feature as a JNK inhibitor. An in vivo study showed that this peptide alone was sufficient to inhibit the activation of JNKs in MPTP-treated mice. Furthermore, we showed that this peptide could decrease MPTP-induced injuries to dopaminergic cell bodies and terminals via inhibiting both nuclear and non-nuclear pathways of JNKs.
MATERIALS AND METHODS Animals
Studies were conducted in male C57BL/6 mice (8-10 weeks old, weighing 19-22 g). Five animals were housed, per cage, in a temperature-controlled (251C) room under a 12:12-h light/dark cycle with ad libitum access to food and water for 1 week before the experiment. The mice were injected intraperitoneally (i.p.) five times (for 5 consecutive days) with 30 mg/kg/day MPTP-HCl (Sigma, St Louis, MO, USA) or a corresponding volume of saline alone. At the indicated time points, the animals were killed, and their brains were processed for further analysis.
Materials
Mouse monoclonal anti-p-JNKs (sc-6254), mouse monoclonal anti-p-c-Jun (sc-822), rabbit polyclonal anti-Fas L (sc-6237), rabbit polyclonal anti-p-Bcl-2 (Ser87), rabbit polyclonal anti-Fas (sc-716), rabbit polyclonal anti-c-Jun (sc-1694), rabbit polyclonal anti-JIP-1 (sc-15353), rabbit polyclonal anti-actin (sc-10731) and rabbit polyclonal anti-PARP (sc-7150) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal anti-Bax (no. 2772), rabbit polyclonal anti-Cytochrome c (no. 4272), rabbit polyclonal anti-cleaved Caspase3 (no. 9661) and rabbit polyclonal anti-Caspase3 (no. 9660) was obtained from Cell Signal Biotechnology (Cell Signaling Technology, Danvers, MA, USA). Rabbit polyclonal anti-JNK3 antibody (06-749) was obtained from Upstate Biotechnology (Dundee, UK). The secondary antibodies used in our experiment were goat anti-mouse IgG and goat anti-rabbit IgG. They were from Sigma-Aldrich China (Shanghai, China). ApopTag Peroxidase In situ Apoptosis Detection Kit (S7100) was purchased from Chemicon International (Temecula, CA, USA).
Cloning of JNK3, JNK2 and GST-JIP1 (127-282) JNK3 (Ser40-Gln422), JNK2 (full legnth) and JIP1(127-282) cDNA were obtained through RT-PCR, then were inserted into vectors pET-28a (Novagen) and pGEX-5X-1 (Amersham-Pharmacia Biotech), respectively. Owing to the poor solubility of full-length JNK3 (Met1-Gln422) (data not shown), we constructed a vector, which expressed JNK3 (Ser40-Gln422) (JNK3a1) truncated protein (Ser40-Gln422) as described in Xie et al.
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Expression and Purification of Truncated JNK3 and GST-JIP1 (127-282) Escherichia coli. strain BL21(DE3) (Novagen) transformed with the truncated JNK3 (Ser40-Gln422), JNK2 (full length) and GST-JIP1 (127-282) expression construct were grown at 371C in shaker flasks in Luria broth. At A600 ¼ 0.4 culture was induced with 0.1 mM (final concentration) of isoproplthion-b-D-galactoside (IPTG, Sigma) and grown with shaking at 181C overnight and harvested at 41C by centrifugation.
Cell pellets from a 100 ml culture were resuspended in 5 ml lysis buffer (50 mM NaH 2 PO 4 , pH 7.5, 300 mM NaCl, 10 mM imidazole, 1 mM PMSF) and were then sonicated 6 Â 10 s with 10 s pauses at 200-300 W. Lysates were centrifuged at 4000 r.p.m. at 41C for 30 min. The supernatants obtained from centrifugation were mixed with Ni-NTA agarose (Qiagen) or glutathione agarose (GE-Healthcare) and then incubated with shaking at 41C for 60 min. After loading the mixture into an empty column, the matrix was washed with wash buffer and the truncated JNK3, full length of JNK2 or GST-JIP1 (127-282) protein was eluted with elution buffer. Protein fractions were analyzed by SDS-PAGE and Coomassie brilliant blue staining.
GST Pull-Down Assays
To assess the inhibitory function of Tat-JBD toward JNK3a1 or JNK2, we performed pull-down assays. Initially, JNK3a1 or JNK2 was preincubated with peptide of Tat-JBD (ArgGST-JIP1 (127-282) fusion proteins bound to glutathione agarose beads were incubated with JNK3a1 þ Tat-JBD, JNK3a1 þ Tat-JBD-4A, JNK2 þ Tat-JBD and JNK2 þ Tat-JBD-4A at RT for 2 h, respectively. The beads were washed by 1 Â PBS buffer and eluted with elution buffer (50 mM TrisHCl, 10 mM-reduced glutathione, pH 7.5). Proteins were analyzed by SDS-PAGE and Coomassie blue R250 staining.
Drug Treatment
Peptide Tat-JBD (100 mg) or control peptide (100 mg) was dissolved in 4 ml 0.9% saline. Drug infusions were performed using a microinjector through cerebral ventricles (from the bregma: anteroposterior, À0.8 mm; lateral, 1.2 mm; depth, 2.8 mm). Four microliter of each peptide was infused over 5 min. Tat-JBD or Tat-JBD-4A were given once per day for 5 consecutive days in a successful PD model and infusion of 0.9% saline served as a vehicle control.
Tissue Preparation
Mice were killed on day 11 under anesthesia, and then substantia nigra pars compacta (SNc) and striatal tissue were isolated and immediately frozen in liquid nitrogen. The SNc and striatum were homogenized in ice-cold homogenization buffer (buffer A) containing 50 mM 3-(N-morpholino) propanesulfonic acid (Sigma; pH 7.4), 100 mM KCl, 320 mM sucrose, 50 mM NaF, 0.5 mM MgCl 2 , 0.2 mM dithiothreitol, 1 mM ethylenediamine tetra acetic acid (EDTA), 1 mM ethylene glycol tetra acetic acid (EGTA), 1 mM Na 3 VO 4 (Sigma), 20 mM sodium pyrophosphate, 20 mM b-phosphoglycerol, 1 mM p-nitrophenyl phosphate, 1 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 5 mg/ml each of leupeptin, aprotinin and pepstatin A. The homogenates were centrifuged at 1000 g for 10 min at 41C. Cytosolic fractions in the supernatants were collected, and protein concentrations were determined. The samples were stored at À801C until further use. These were performed as per the protocol of our previous study. [22] [23] [24] [25] Crude Mitochondrial Fraction Extraction Tissue samples for western blot analysis of cytochrome c (cyt c) were immediately isolated to prepare subcellular fractions. All procedures were conducted in a cold room. Non-frozen brain tissue was used to prepare mitochondrial fractions because freezing tissue causes release of cyt c from mitochondria. The tissue samples were homogenized in 1:10 (w/v) cold homogenization buffer A. The homogenates were centrifuged at 1000 g for 10 min at 41C. The pellets were discarded and supernatants were further centrifuged at 17 000 g for 20 min at 41C to yield the cytosolic fraction in the supernatants and the crude mitochondrial fraction in the pellets. 22 
Nuclear Extraction
Tissue homogenates were centrifuged at 1000 g for 10 min, the pellets were extracted with 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.9, 20% glycerol, 420 mM NaCl, 0.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT and enzyme inhibitors for 30 min at 41C with constant agitation. After centrifugation at 12 000 g for 15 min at 41C, the nuclear fraction in the supernatants was collected, and the protein concentrations were determined. The samples were stored at À801C and were thawed only once. [22] [23] [24] [25] Immunoprecipitation and Immunoblotting Tissue homogenates (400 mg of protein) were diluted fourfold with 50 mM HEPES buffer (pH 7.4), containing 10% glycerol, 150 mM NaCl, 1% Triton X-100, 0.5% NP-40, and 1 mM each of EDTA, EGTA, PMSF and Na 3 VO 4 . Samples were preincubated for 1 h with 20 ml protein A sepharose CL-4B (Amersham, Uppsala, Sweden) at 41C, and then centrifuged to remove proteins adhered non-specifically to protein A. The supernatants were incubated with 1-2 mg primary antibodies for 4 h or overnight at 41C. Protein A was added to the tube for another 2-h incubation. Samples were centrifuged at 10 000 g for 2 min at 41C and the pellets were washed with HEPES buffer three times. Bound proteins were eluted by boiling at 1001C for 5 min in SDS-PAGE loading buffer and then isolated by centrifugation. The supernatants were used for immunoblotting analysis. Proteins were separated on polyacrylamide gels and then electrotransferred onto a nitrocellulose membrane (Amersham, Buckinghamshire, UK). After being blocked for 3 h in Tris-buffered saline with 0.1% Tween 20 (TBST) and 3% bovine serum albumin (BSA), membranes were incubated overnight at 41C with primary antibodies in TBST containing 3% BSA. After washing for 30 min in TBS with gentle agitation, the membrane was incubated with horseradish peroxidase-conjugated anti-mouse/rabbit IgG secondary antibody at room temperature for 2 h. Signals were developed using ECL western blotting detection kit (Amersham-Pharmacia Biotech, Little Chalfont, UK). Band intensities were quantified by densitometric analyses using an AxioCam digital camera (ZEISS, CTED PROOF Germany) and a KS400 photo analysis system (Version 3.0).
Histological Assessment and Immunohistochemistry
Mice were perfusion-xed on day 11 with 4% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4). Brains were removed quickly and further xed with the same xation solution at 41C overnight. Post-xed brains were embedded by paraffin, followed by preparation of coronal sections using a microtome. The paraffin-embedded brain sections were deparaffinized with xylene and rehydrated by ethanol at graded concentrations of 100-70% (v/v), followed by washing with water.
Immunoreactivity was determined by the avidin-biotinperoxidase method. Briefly, sections were deparaffinized with xylene and rehydrated by ethanol at graded concentrations and distilled water. High-temperature antigen retrieval was
The role of JNKs in MPTP injury in vivo J Pan et al performed in 1 mM citrate buffer for 15 min. To block endogenous peroxidase activity, sections were incubated for 30 min in 1% H 2 O 2 . After being blocked with 5% (v/v) normal goat serum in PBS for 1 h at 371C, sections were incubated with a mouse polyclonal antibody against tyrosine hydroxylase (TH, 1:8000) at 41C for 24 h. These sections were then incubated with biotinylated goat-anti-mouse secondary antibody overnight and subsequently with avidin-conjugated horseradish peroxidase for 1 h at 371C. Finally, sections were incubated with peroxidase substrate diaminobenzidine until the desired stain intensity developed.
TUNEL staining was performed using an ApopTag Peroxidase in situ apoptosis detection kit according to the manufacturer's protocol with minor modifications. The paraffin-embedded coronal sections were deparaffinized and rehydrated, and then treated with protease K at 20 mg/ml for 15 min at room temperature. Sections were incubated with the reaction buffer containing TdT enzyme and at 371C for 1 h. After washing with stop/wash buffer, sections were treated with anti-digoxigenin conjugate for 30 min at room temperature and subsequently developed color in peroxidase substrate. The nuclei were lightly counterstained with 0.5% Methyl Green.
TH-Positive Cell and TUNEL-Positive Cell Counting
To confirm the protection effect of Tat-JBD, the total number of dopaminergic neurons in the SNc was counted through the method of Furuya et al 26 in four mice per group. In brief, immunohistochemistry was performed as described above in 20-mm thick nigral coronal sections. TH-positive neurons were counted in the right and left SNc of every fourth section throughout the entire extent of the SNc. The number of TH-positive cells were counted manually with 'Image Tool' of UTHSCSA (The University of Texas Health Science Center The role of JNKs in MPTP injury in vivo J Pan et al at San Antonio) by researchers blinded to the treatment schedule. 27 Four coronal sections (one of every two sections) of the middle part of substantia nigra from each animal were used for TUNEL staining with apoptosis detection kit of Chemicon International. The number of TUNEL-positive cells within the anatomical boundaries of SNc were counted with the aid of 'Image Tool' too. 28 The total number of TH-positive and TUNEL-positive cells in different groups of mice were compared.
Statistical Evaluation
Values were expressed as mean s.d. and obtained from at least six independent experiments. Statistical analysis of the results was carried out by Student's t-test or one-way analysis of the variance followed by the Duncan's new multiple range method or Newman-Keuls test. P-values o0.05 were considered significant.
RESULTS

Tat-JBD Suppresses JNK Activation
To disrupt the interaction between JIP-1 and JNK, we constructed a peptide comprising residues 153-163 of murine JIP-1, which was conserved in sapiens and rodents. Tat peptide, which was obtained originally from the cell-membrane transduction domain of the human immunodeficiency virus-type 1 (HIV-1), was fused to JBD and resulted in a 22-amino acid fusion peptide, Tat-JBD.
We first examined the distribution of the peptides in the brain of the mouse. The fluorophore dansyl chloride was conjugated to Tat-JBD and Tat-JBD-4A, respectively. Fluorescence can be observed in SNc of mice subjected cerebral ventricular injection of Tat-JBD-dansyl and Tat-JBD-4A-dansyl, whereas the same region showed only a background signal in the mice treated with saline ( Figure 1a and b) . To elucidate the effects of Tat-JBD on the activation of JNKs, JNK1/2/3 phosphorylations were investigated in MPTPlesioned animals. As indicated in Figure 1c -f, the results of western blotting showed that the phosphorylation and total level of JNKs especially JNK3 were significantly increased after MPTP injection. However, as shown in Figures 1c-f , the treatment of Tat-JBD remarkably inhibited the phosphorylation of JNK3 as well as JNK1 and 2. The same dose of Tat-JBD-4A did not have the same effect. The protein levels of JNKs were not affected by either Tat-JBD or Tat-JBD-4A treatment.
Tat-JBD Perturbs the Assembly of JIP-1-JNK Complex
Owing to the poor solubility of expressed full-length JNK3 (data not shown), we expressed the truncated JNK3a1, which encodes amino acid residues Ser40-Gln422 of JNK3 as described in Xie et al. 21 Their result already has proved that JNK3 protein lacking the N-terminal 39 residues displayed the similar kinase activity to the JNK3 protein in vitro. Purified His-JNK3a1 was incubated with control peptide and Tat-JBD. The result of GST-JIP1 (127-282) pull-down assay indicated that JBD peptide could suppress the interaction between JNK3 and JIP-1 in vitro (Figure 2a) . To detect whether Tat-JBD could inhibit JNK2 interaction with JIP-1 either, we expressed the full length of JNK2. Purified His-JNK2 was incubated with control peptide and Tat-JBD, respectively. The result of GST-JIP1 (127-282) pull-down assay indicated that JBD peptide could also suppress the interaction between JNK2 and JIP-1 in vitro (Figure 2b) .
We next investigated whether Tat-JBD could perturb the assembly of JIP-1-JNK complexes by examining its effects on the co-immunoprecipitation of JIP-1 with JNK in vivo. The cytosolic protein fraction of mice SNc tissue were from animal models treated with either Tat-JBD or control peptide (Tat-JBD-4A). Results from co-immunoprecipitation indicated that control peptide lacking an intact JNK-binding motif could not suppress the interaction of JNK3 or JNK1/2 with JIP-1, whereas the same dose of Tat-JBD could noticeably suppress their interaction (Figure 2c and d) .
Tat-JBD Modulates MPTP-Induced c-Jun Phosphorylation and Fas L Expression
To elucidate the effects of Tat-JBD on the activation and expression of c-Jun, the nuclear substrate of JNKs, c-Jun phosphorylation was detected in MPTP-lesioned animals. As indicated in Figure 3a and b, results of western blotting revealed that the phosphorylation and total amount of c-Jun Tat-JBD Inhibits the Phosphorylation of Bcl-2 and the Release of Bax from Bcl-2/Bax Dimmers Our previous study indicated that K252a (the inhibitor of JNK upstream) rescued 6-OHDA-induced dopaminergic neuronal death in SNc via suppressing the phosphorylation of Bcl-2. 21 Consistent with that result, MPTP lesion can also increase the level of phosphorylated Bcl-2 and decrease the interaction of Bcl-2 with Bax. The application of Tat-JBD can inhibit the phosphorylation of Bcl-2 and sequentially suppress the releasing of Bax from Bcl-2/Bax dimmers (Figure 4a and b) .
Tat-JBD Attenuates Bax Translocation and the Release of Cytochrome c
To elucidate the involvement of mitochondria-mediated apoptotic pathway during MPTP lesion and the action of JNK activity on Bax translocation and the release of cyt c, level of Bax and cyt c in mitochondria and cytosol was The role of JNKs in MPTP injury in vivo J Pan et al examined by western blotting. We first determined whether Bax translocates from cytosol to mitochondria after lesion. Using western blotting analysis on different subcellular fractions, we found that the level of Bax was significantly increased in the mitochondria, but not markedly decreased in cytosol (Figure 5a and b) . This can be explained by the fact that the overwhelming amount of Bax was located in cytosol, thus partial translocated Bax did not noticeably affect the total protein level of Bax in cytosol. Moreover, we examined whether the inhibition of JNKs by Tat-JBD contributes to attenuating Bax translocation. The inhibitory effect of Tat-JBD on Bax translocation in the mitochondrial fraction reached a statistical difference compared with that of the control peptide Tat-JBD-4A (Figure 5a and b) . A significant amount of mitochondrial cyt c was detected in the saline controls. This portion of cyt c was decreased after MPTP treatment, corresponding to a marked increase in the cytosolic fraction (Figure 5c and d) . The inhibitory effect of Tat-JBD on the release of cyt c in the cytosol fraction reached a statistical difference compared with the control peptide Tat-JBD-4A (Figure 5c and d) . To elucidate whether other mitochondrial proteins were released from mitochondria, we determined the cyt c oxidase level in the cytosolic and mitochondrial fraction using cyt c oxidase subunit IV antibody. The cyt c oxidase subunit IV was detected only in the mitochondrial fraction but not in the cytosolic fraction in saline, MPTP lesion or application of peptide groups (Figure  5a-d) . These results suggested that cyt c oxidase was not coreleased with cyt c from mitochondria.
Tat-JBD Decreases the Activation of Caspase3
Caspase3 is one of the key executioners in the apoptotic pathway and is a cytosolic protein as an inactive 32 kDa proenzyme. It is activated by proteolytic cleavage into the 20 kDa (p20) and 11 kDa (p11) active subunits. During apoptosis, caspase3 cleaves the substrate 116 kDa poly-ADPribose-polymerase (PARP) into an 85 kDa and a 25 kDa fragment. In this study, we examined the activation of caspase3 and PARP in MPTP lesion and the inhibition of peptide on caspase3 activation and hydrolyzation of PARP using western blot analysis. As shown in Figure 6a and b, the increase of cleaved caspase3 and hydrolyzation of PARP were obviously suppressed by the treatment of peptide Tat-JBD. The same dose of control peptide Tat-JBD-4A did not affect the increase of cleaved caspase3 and hydrolyzation of PARP. (Figure 7a(B) ). However, administration of Tat-JBD clearly rescued the neurodegeneration caused by MPTP (Figure 7a(D) ). At the same time, as the control, Tat-JBD-4A did not show any protection (Figure 7a(C) ). The results indicated that Tat-JBD was capable of protecting neurons against MPTP-induced injury. TH immunostaining in the striatum was assessed as an indication of dopaminergic axon. The results revealed that Tat-JBD treatment minimized the decreased densities of dopaminergic axon in the caudateputamen (CP) region of the striatum (Figure 7a(D 1 ) ), whereas the Tat-JBD-4A did not have such effect (Figure 7a(C 1 ) ).
Mice were perfusion-xed with paraformaldehyde and TUNEL staining was used to examine the apoptosis of dopaminergic neurons in SNc (Figure 7b) . A significant number of positive cells were observed (Figure 7b(B, B 2 ) ). Some of them showed characteristic appearances, such as shrunken, condensed nuclei and apoptotic bodies. However, others revealed lightly stained, large and swollen nuclei, as the results showing the administration of Tat-JBD significantly decreased TUNEL-positive cells (Figure 7b(D, D 2 ) ). At the same time, we examined the effect of Tat-JBD on TH-positive neurons in SNc of MPTP mouse. The results indicated that Tat-JBD was capable of protecting neurons against MPTPinduced injury.
DISCUSSION
Various mechanisms have been proposed to account for the neurodegeneration induced by MPTP. Early studies suggested that MPTP-induced neuronal damage in vitro was because of the activation of JNK-signaling pathway. The JNKs, first characterized by their activation following exposure to various forms of cellular stress, are now suggested to have important roles in the regulation of neuronal death including nigral dopaminergic neurons.
There are three isoforms of JNKs, JNK1, JNK2 and JNK3, which has distinct roles. 8, 29, 30 JNK1 is primarily responsible for the level of basal JNK activity in the brain, 30 whereas the activated JNK2 and JNK3 proved to be related to neuronal death in 6-OHDA-treated mice. 31 As aforementioned, targeted disruption of the Jnk3 gene not only reduced the downstream effector c-Jun phosphorylation, but also remarkably protected mice from brain injury after MPTP lesion. 9 These studies indicated the functional diversity of JNK isoforms and suggested that the activation of JNKs is a critical factor in PD pathogenesis. The level of phosphorylated JNKs is increased in our MPTP mice also showed the role of activated JNKs in neuronal death in the PD animal model.
A number of studies including ours already showed that the activation of JNK relies on the formation of JNK cascade and is related to neuronal death. 32 JIP-1 is believed to interact with MLK3, MKK7 and JNK, help to form the JNK-signaling module and facilitate the activation of JNK signaling. 33, 34 Disrupting the interaction between JIP-1 and any kinase in JNK cascade will inhibit the activation of JNKs effectively. In recent years, more attention has been paid to the effect of the peptides derived from JBD (JIP-1 127-281), which perturbs the assembly of JIP-1-JNK complexes, on the therapy of various diseases. Furthermore, Barr et al 20 found that a shorter peptide corresponding to the sequence 153-163 of JIP-1 also effectively inhibit JNK activity in vivo. It indicated that this region is responsible for the interaction between JIP-1 and JNKs.
On the basis of the above-mentioned findings, we synthesized a new peptide Tat-JBD. The membrane transduction domain of the HIV-1 was fused to the peptide to help the peptide enter the cells easily. Fluorescence examination showed that Tat-JBD could enter the cells effectively and localized at SNc when it was injected through cerebral ventricular in MPTP mice. Both in vitro and in vivo studies show that treatment of the peptide Tat-JBD can inhibit the binding between JIP-1 and JNKs and attenuate the activation of JNKs induced by MPTP lesion. The activation of JNK2 and JNK3 were thought to be responsible for the dopamine neuron death in MPTP mice. In our experiment the phosphorylation level of JNK3 is higher than that of JNK1 and JNK2. Furthermore, it is wellknown that the products of the JNK1 and JNK2 genes are ubiquitously expressed, whereas the expression of JNK3 is restricted predominantly to the brain. 8 All these indicate that JNK3 may have a more important role than JNK1/2 in MPTP-induced dopaminergic neuronal death.
Nevertheless, the downstream mechanism that accounts for the proapoptotic actions of JNK remains to be investigated in detail. 35, 36 This study showed that treatment of Tat-JBD attenuated the increased phosphorylation of c-Jun induced by MPTP lesion in SNc. Activated JNK phosphorylates the transcription factor c-Jun and leads to the increase of AP-1 transcription activity to modulate transcription of a number of genes such as Fas L. [37] [38] [39] Results from our present study suggested that through c-Jun/AP-1-mediated transcriptional regulation, activation of JNKs may enhance the expression of Fas L, which can ultimately contribute to Fas receptor-mediated apoptosis. Taken together, these results suggest that the nuclear signal pathway mediated by JNKs activation is involved in dopaminergic neuronal death induced by MPTP.
Besides the nuclear pathway, JNKs can also promote cell death by regulating the activation of some non-nuclear substrates, such as Bcl-2 family members. 38, 40 Previous studies have also indicated that phosphorylation inactivates Bcl-2, thus promoting apoptosis, possibly by releasing Bax from Bcl-2/Bax dimmers. 38, 41, 42 The Bcl-2/Bax heterodimer is the active component for death protection. 43, 44 In response The role of JNKs in MPTP injury in vivo J Pan et al to apoptotic stimulation, Bax can be released from Bcl-2/Bax dimmers and act as the channels for either ions or proteins. 38, 45 This proapoptotic protein Bax forms pores in the outer mitochondrial membrane which helps in the releasing of cyt c. 46 As Tat-JBD could inhibit the activation of JNK, we showed that treatment of the peptides inhibited the phosphorylation of Bcl-2 proteins, increased the interaction of Bcl-2 with Bax, prevented Bax translocation to mitochondria, and attenuated the release of cyt c and caspase-3 activation. 14, 19, 39, 42 This suggests that the mitochondriadependent apoptosis pathway mediated by JNKs activation is also involved in dopaminergic neuronal apoptosis induced by MPTP-injury.
As the treatment of the peptides could inhibit the activation of JNKs induced by MPTP lesion through blocking the interaction between JNKs and JIP-1, we inferred that application of the peptides would also restore dopaminergic terminals as well as SNc cell bodies from degeneration. Our present study proved that the Tat-JBD peptide was capable of preventing dopaminergic neurons from degeneration following MPTP insult. Moreover, TUNEL results provided strong evidence that the peptide could protect the dopaminergic neurons from apoptosis. As significant neuroprotection was achieved by Tat-JBD at the onset of PD, Tat-JBD shows great clinical relevancy and provides a novel way for the treatment of PD.
